820-3120

DSM, Corporate Communications

P.O. Box 6500, 6401 JH Heerlen, The Netherlands Telephone (31) 45 5782422, Telefax (31) 45 5740680

Internet: www.dsm.ce E-mail: press.o

11E

กรถรถ893

03 MAY 13 AT 7:21

DSM 👂



28 April 2003

First-quarter net profit EUR 73 million, 7% higher than in Q1 2002

- Sales up 7%, mainly due to autonomous volume growth (9%).
- Operating profit from ongoing activities 12% higher than in Q1 2002.
- Second-quarter operating profit seems to be developing around the level of the first quarter of 2003.

EUR million	first	quarter	
	2003	2002	+/-
Ongoing activities:			
Net sales	1,453	1,360	7%
Operating profit plus depreciation & amortization (EBITDA)	187	180	4%
Operating profit before amortization of goodwill (EBITA)	97	88	10%
- Life Science Products	52	53	-2%
- Performance Materials	34	28	21%
- Industrial Chemicals	21	7	200%
- Other activities	-10	0	
Operating profit (EBIT)	91	81	12%
Discontinued activities (DSM Petrochemicals):	******		
Net sales	•	471	
Operating profit plus depreciation & amortization (EBITDA)	-	42	
Operating profit (EBIT)	•	12	
Total DSM:			
Net sales	1,453	1,831	
Total operating profit (EBIT)	91	93	
Total operating profit (EBIT) Profit on ordinary activities after taxation JUN 03 2003	72	68	
Extraordinary profit after taxation	-	-	
Net profit	73	68	7%
Per ordinary share in EUR:			
- profit on ordinary activities after taxation	0.69	0.65	
- net earnings	0.70	0.65	
Average number of ordinary shares (x million)	96.0	96.3	

 $\bigcap \bigcap \bigcap \bigcap \bigcap \bigcap$

First-quarter net profit EUR 73 million, 7% higher than in Q1 2002

General

In the first quarter of 2003 DSM posted an operating profit from ongoing activities of EUR 91 million, which is EUR 10 million higher than in the first quarter of 2002. The net profit on ordinary activities amounted to EUR 72 million, which is EUR 4 million (6%) higher than in Q1 2002. Total net profit amounted to EUR 73 million due to minority interests.

Commenting on the results, DSM Managing Board Chairman Peter Elverding said: "The first quarter was characterized by a strongly declined dollar exchange rate, high raw-material prices and hesitant economic conditions. In addition, we faced one-off costs relating to a business interruption at DSM Chemicals Rotterdam. Against this background, the first quarter was satisfactory for DSM. Both our operating profit and our net profit were higher than in the first quarter of 2002. In the first quarter we were able to profit immediately from slight improvements in some markets, as indicated by our strong autonomous volume growth of 9%.

However, market prospects continue to be so uncertain that, despite the encouraging first-quarter result, we are unable to make a statement yet about the whole of 2003. The second-quarter operating profit seems to be developing around the level of the first quarter of 2003."

Net sales (ongoing activities)

EUR million	first	first quarter		
	2003	2002		
Life Science Products	503	517		
Performance Materials	458	449		
Industrial Chemicals	388	291		
Other activities	104	103		
Total	1,453	1,360		

Net sales in the first quarter of 2003 were up 7% from the first quarter of 2002. The main contributing factors were the autonomous volume growth in all clusters (overall autonomous growth being 9%) and a 5% increase in average selling prices. Lower exchange rates for the US dollar, the pound sterling and the yen had a negative effect of 7%.

Operating profit

The operating profit from ongoing activities for the first quarter was EUR 91 million, which is 12% higher than in Q1 2002. The increase in operating profit was mainly a result of higher sales volumes. Despite an increase in average selling prices, margins were on balance lower due to a very strong increase in raw-material prices.



Review by cluster

Life Science Products

EUR million	first quarter		
	2003	2002	
Net sales including intra-Group supplies	516	531	
Operating profit plus depreciation and amortization	92	90	
Operating profit	52	53	

Despite a 4% increase in sales volumes, sales of this cluster decreased by 3% compared with Q1 2002 due to the effect (-7%) of lower exchange rates. The operating profit remained at the level of Q1 2002. The EBITDA margin (EBITDA / net sales) was 18%. DSM Pharmaceutical Products felt the effects of the delay in the introduction of new products in the pharmaceutical industry and the resulting overcapacity. As a consequence, it posted a negative operating result. Improvements are expected in the next few quarters. In view of the situation in the market, restructuring measures are being prepared. Whereas the branded pharmaceutical products of DSM Pharmaceutical Products were under pressure, DSM Anti-Infectives' generic products showed a very strong performance. This business group posted a strong increase in sales and operating profit compared with the first quarter of 2002, due in part to strongly increased sales of clavulanic acid and the effect of the restructuring operations that have been implemented successfully since early 2000. DSM Food Specialties saw its sales and operating profit decrease as a result of the weaker dollar. The operating profit of DSM Fine Chemicals and DSM Bakery Ingredients was at the same level as in Q1 2002.

Performance Materials

EUR million	first quarter		
	2003	2002	
Net sales including intra-Group supplies	459	462	
Operating profit plus depreciation and amortization	54	50	
Operating profit	34	28	

This cluster's sales in the first quarter of 2003 were at the Q1 2002 level. Higher sales volumes for virtually all activities (overall volume growth 9%) compensated for the effect of the lower exchange rate for the US dollar and the lower selling prices at DSM Elastomers and DSM Coating Resins. With the exception of DSM Elastomers, which saw its margins decrease, all units posted a higher operating profit than in Q1 2002. The operating profit for the cluster was also substantially above the level of Q4 2002.

Industrial Chemicals

EUR million	first quarter		
	2003	2002	
Net sales including intra-Group supplies	421	318	
Operating profit plus depreciation and amortization	42	29	
Operating profit	21	7	

This cluster's sales and operating profit showed a very strong increase compared with the Q1 2002 level as a result of higher sales volumes and selling prices. Sales increased by EUR 25 million due to the consolidation of DSM Nanjing Chemical Company (a caprolactam producer). All business groups performed better than in Q1 2002, with the exception of DSM Energy, whose oil and gas production decreased. After having been in the red for several quarters, DSM Agro once again posted a positive operating result.

Other activities

EUR million	first	
	2003	2002
Net sales including intra-Group supplies	104	104
Operating profit plus depreciation and amortization	-1	11
Operating profit	-10	0

The negative operating result of Other activities was due to the fact that part of the financial damage caused by a fire at DSM Chemicals Rotterdam was borne by DSM's captive insurance company.

In the second quarter of 2003 a serious accident occurred at DSM Melamine in Geleen (Netherlands), which sadly resulted in three fatalities. Part of the damage to the melamine plant, will also be borne by the captive insurance company in the second quarter, which will have a comparable negative effect.

Net profit

The *Balance of financial income and expense* amounted to an interest expense of EUR 1 million, which is EUR 7 million lower than in Q1 2002. This improvement was due to an increase in financial income resulting from the investment of the revenues from the sale of DSM Petrochemicals.

At 22%, the *effective tax rate* in Q1 2003 was higher than in Q1 2002 (18%). The increase was due to the decrease in the proportion of profit elements taxed at a low rate.

The *Profit from non-consolidated companies* improved by EUR 4 million, mainly because of the higher result of Methanor.

Net profit increased by EUR 5 million (7%) compared with Q1 2002 and stood at EUR 73 million.

Cash flow, capital expenditure and financing

In Q1 2003 the cash flow (net profit plus depreciation and amortization) amounted to EUR 169 million, EUR 28 million less than in Q1 2002, when the cash flow still included the contribution from DSM Petrochemicals. At EUR 90 million, capital expenditure was slightly below the level of depreciation and amortization.

The net surplus decreased due to the consolidation of the net debt of DSM Nanjing Chemical Company (China).

Workforce

As a result of consolidations (mainly DSM Nanjing Chemical Company) the workforce increased by 1,136. The organic decrease amounted to 290.

Progress made in acquisition of Roche's vitamins, carotenoids and fine chemicals business

Following the signing of the contract on 10 February 2003, DSM and Roche took the various steps necessary to obtain the authorities' approval.

Outlook

The general economic outlook and trading conditions in DSM's main end markets continue to be hesitant and uncertain. The first quarter showed a stable profit development despite the much weaker dollar and higher raw-material prices. It is still too early now to draw conclusions from this for DSM for the whole year 2003. The picture that emerges for the various clusters is as follows.

The Life Science Products cluster is expected to post an operating profit for the whole of the year which, barring a strong further decrease in the dollar exchange rate, will be at the 2002 level, the expectation being that the second half of the year will be better than the first half.

For the Performance Materials and Industrial Chemicals clusters, developments in sales volumes to the automotive industry and the E&E industry and in raw material prices are uncertain factors.

DSM's operating profit for the second quarter seems to be developing around the level of the first quarter of 2003.

Heerlen, 28 April 2003 The Managing Board of Directors

DSM 🚯

Important dates:

Publication of second-quarter results: Interim dividend 2003: Publication of third-quarter results: Annual Report 2003: Annual General Meeting: Friday, 25 July 2003 Monday, 11 August 2003 Monday, 27 October 2003 Wednesday, 11 February 2004 Wednesday, 31 March 2004

For more information:

Media

DSM, Corporate Communications, Tel. (31) 45 5782424, fax (31) 45 5740680 E-mail: media.relations@dsm.com

Investors

DSM Investor Relations
Tel. +31 (45) 5782864, fax +31 (45) 5782595
E-mail: investor.relations@dsm.com

Internet: www. dsm.com

Consolidated statement of income (2002: including discontinued activities)

	first quarter		
EUR million	2003	2002	
net sales	1,453	1,831	
operating profit plus depreciation and amortization	187	222	
operating profit before amortization of goodwill (EBITA) amortization of goodwill	97 6	100 -7	
operating profit (EBIT) balance of financial income and expense	91 1	93 -8	
profit on ordinary activities before taxation taxes on profit on ordinary activities profit from non-consolidated companies	90 -20 2	85 -15 -2	
profit on ordinary activities after taxation extraordinary profit after taxation	72 	68	
group profit after taxation minority interests' share	72 1	68	
net profit	73	68	
net profit	73	68	
dividend on cumulative preference shares	6	-6	
net profit available to holders of ordinary shares	67	62	
cash flow	169	197	
depreciation and amortization capital expenditure	96 90	129 115	
per ordinary share in EUR*:			
profit on ordinary activities after taxationnet earningscash flow	0.69 0.70 1.70	0.65 0.65 1.99	
average number of ordinary shares (x million) number of ordinary shares at end of quarter (x million)	96.0 94.4	96.3 96.3	
workforce of which in the Netherlands * After deduction of dividend on cumulative preference shares.	19,221 8,250	**18,375 **8,302	

Year-end 2002.

DSM 🕏

Consolidated balance sheet

EUR million	end of Mar	ch 2003	year-e	nd 2002
fixed assets intangible fixed assets	457		462	
tangible fixed assets	2,958		2,885	
financial fixed assets	238		292	
		3,653		3,639
current assets	070		044	
inventories receivables	972 1,483		944 1,439	
cash / marketable securities	2,969		2,974	
		5,424		5,357
Total		9,077		8,996
EUR million	end of Mar	ch 2003	year-e	end 2002
group equity	•			
group equity shareholders' equity	5,107		5,142	
minority interests' share	67		44	
		5,174		5,186
equalization account		36		32
provisions		629		682
long-term liabilities current liabilities		1,439		1,337
- interest-bearing	646		599	
- non-interest-bearing	1,153		1,160	
		1,799		1,759
Total				8,996
Total		9,077		0,990
		·		
capital employed net debt		9,077 4,717 -884		4,570
capital employed		4,717		4,570 -1,038 0.58 -0.25

The financial information set out in this quarterly report has not been audited.

DSM 🕟

Statement of cash flows

	first quarter			•
EUR million		2003		2002
Cash at beginning of period		2,974		1,148
Operating activities: - cash flow - change in working capital - other changes	169 -100 -31		197 34 -71	
Net cash provided by operating activities		38		160
Investing activities: - capital expenditure - divestments - other changes	-90 8 9		-115 12 -11	
Net cash used in investing activities		-73		-114
Dividend paid		-		-
Net cash provided by / used in financing activities Effects of change in consolidation		-9 39		80 -3
Cash at end of period		2,969		1,271

Statement of changes in shareholders' equity

	first quarter		
EUR million	2003	2002	
Shareholders' equity at beginning of period	5,142	4,239	
Changes:			
- net profit	73	68	
- dividend	-6	-119	
- exchange rate differences	-28	2	
- share buy-backs	-76	-3	
- other	2	9	
Shareholders' equity at end of period	5,107	4,196	

The finencial information act out in this quarterly report has not been audited.